Inspire Medical Systems, Inc. is focused on delivering a breakthrough treatment for people with obstructive sleep apnea (OSA). As a result of this commitment, Inspire is leading the way with a groundbreaking advance in OSA treatment.
Inspire developed the world’s first fully implanted neurostimulation device approved by the FDA for the treatment of OSA. The Inspire system uses well-established neurostimulation technologies and incorporates a proprietary algorithm that stimulates key airway muscles based on a patient’s unique breathing patterns. Inspire therapy is designed to reduce OSA severity and improve quality of life for patients living with this challenging condition.
Inspire was formed in 2007 when the technology and a significant intellectual property portfolio were spun out of Medtronic (NYSE: MDT).
Latest funding size
Time since last funding
|Kleiner Perkins Caufield & Byers, U.S. Venture Partners (USVP), Johnson & Johnson Development Corporation, Medtronic, Synergy Life Science Partner, GDN Holdings, TGap Ventures, Aperture Venture Partners, OrbiMed|